Shoulder Innovations, Inc. (NYSE:SI – Get Free Report) CEO Robert Ball sold 10,175 shares of the company’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $18.45, for a total transaction of $187,728.75. Following the sale, the chief executive officer directly owned 380,824 shares of the company’s stock, valued at $7,026,202.80. The trade was a 2.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shoulder Innovations Stock Performance
NYSE:SI opened at $17.98 on Wednesday. The company has a market cap of $374.34 million, a P/E ratio of -9.36 and a beta of -1.77. Shoulder Innovations, Inc. has a twelve month low of $10.92 and a twelve month high of $24.59. The company’s 50-day moving average price is $21.07 and its 200-day moving average price is $17.40. The company has a current ratio of 10.71, a quick ratio of 8.92 and a debt-to-equity ratio of 0.12.
Shoulder Innovations (NYSE:SI – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03). The business had revenue of $17.18 million for the quarter. Shoulder Innovations had a negative net margin of 58.33% and a negative return on equity of 23.61%. On average, sell-side analysts forecast that Shoulder Innovations, Inc. will post -1.9 earnings per share for the current fiscal year.
Institutional Trading of Shoulder Innovations
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on SI shares. Weiss Ratings raised Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective (up from $19.00) on shares of Shoulder Innovations in a research note on Friday, August 7th. UBS Group upped their target price on Shoulder Innovations from $27.00 to $28.00 and gave the company a “buy” rating in a report on Monday, August 10th. Finally, BTIG Research raised their target price on Shoulder Innovations from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Shoulder Innovations presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.50.
Read Our Latest Research Report on SI
About Shoulder Innovations
Shoulder Innovations, Inc is a medical device company focused on developing and commercializing orthopedic products for shoulder replacement surgery. The company’s business centers on technologies intended to address conditions such as shoulder arthritis, rotator cuff damage and other causes of shoulder pain and limited mobility.
Its product portfolio includes shoulder arthroplasty systems and related implants, including the InSet glenoid technology and humeral components for anatomic and reverse shoulder replacement procedures.
Recommended Stories
- Five stocks we like better than Shoulder Innovations
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Shoulder Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shoulder Innovations and related companies with MarketBeat.com's FREE daily email newsletter.
